The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs

IF 3.4 2区 医学 Q2 RHEUMATOLOGY Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-05-23 DOI:10.1177/1759720x241253656
Antimo Moretti, Francesco Snichelotto, Sara Liguori, Marco Paoletta, Giuseppe Toro, Francesca Gimigliano, Giovanni Iolascon
{"title":"The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs","authors":"Antimo Moretti, Francesco Snichelotto, Sara Liguori, Marco Paoletta, Giuseppe Toro, Francesca Gimigliano, Giovanni Iolascon","doi":"10.1177/1759720x241253656","DOIUrl":null,"url":null,"abstract":"Musculoskeletal disorders are characterized by several impairments, including pain, affecting muscles, bones, joints and adjacent connective tissue, resulting in temporary or permanent functional limitations and disability. Musculoskeletal pain is particularly prevalent worldwide and greatly impacts the quality of life, social participation and economic burden. To date, several issues persist about the classification of musculoskeletal pain and its management strategies and resources. The treatment of musculoskeletal pain conditions is complex and often requires a multimodal approach, including pharmacological and non-pharmacological therapy that might be ineffective in many cases, resulting in poor patient satisfaction and controversial expectations about the potential benefits of available interventions. This manuscript provides an overview of unmet needs in managing musculoskeletal pain, particularly focusing on pharmacotherapeutic pitfalls in this context.","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720x241253656","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Musculoskeletal disorders are characterized by several impairments, including pain, affecting muscles, bones, joints and adjacent connective tissue, resulting in temporary or permanent functional limitations and disability. Musculoskeletal pain is particularly prevalent worldwide and greatly impacts the quality of life, social participation and economic burden. To date, several issues persist about the classification of musculoskeletal pain and its management strategies and resources. The treatment of musculoskeletal pain conditions is complex and often requires a multimodal approach, including pharmacological and non-pharmacological therapy that might be ineffective in many cases, resulting in poor patient satisfaction and controversial expectations about the potential benefits of available interventions. This manuscript provides an overview of unmet needs in managing musculoskeletal pain, particularly focusing on pharmacotherapeutic pitfalls in this context.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肌肉骨骼疼痛药物疗法面临的挑战:未满足需求概述
肌肉骨骼疾病的特征是影响肌肉、骨骼、关节和邻近结缔组织的若干损伤,包括疼痛,从而导致暂时或永久的功能限制和残疾。肌肉骨骼疼痛在全球尤为普遍,对生活质量、社会参与和经济负担造成极大影响。迄今为止,关于肌肉骨骼疼痛的分类及其管理策略和资源仍存在一些问题。肌肉骨骼疼痛的治疗非常复杂,通常需要采用多模式方法,包括药物和非药物疗法,但在许多情况下,药物和非药物疗法可能是无效的,这导致患者满意度不高,对现有干预措施的潜在益处的预期也存在争议。本手稿概述了在管理肌肉骨骼疼痛方面尚未得到满足的需求,尤其侧重于这方面的药物治疗陷阱。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.80
自引率
4.80%
发文量
132
审稿时长
18 weeks
期刊介绍: Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.
期刊最新文献
Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial. What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes? Imaging in psoriatic arthritis: established methods and emerging techniques. Infections in psoriatic arthritis: association with treatment. Serum transthyretin levels and disease activity in patients with primary Sjögren's syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1